Brainstorm Cell Therapeutics Inc. (BCLI)

Market Cap	9.54M +7.3%
Revenue (ttm)	n/a
Net Income	-10.31M
EPS	-1.11
Shares Out	11.03M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,947
Open	0.7953
Previous Close	0.8500
Day's Range	0.7953 - 0.8723
52-Week Range	0.4589 - 1.3200
Beta	0.28
Analysts	Hold
Price Target	17.00 (+1,866.46%)
Earnings Date	Aug 12, 2026

About BCLI

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company’s NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the deve...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 20
• Stock Exchange: OTCMKTS
• Ticker Symbol: BCLI

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 20, 2026

Data Sources Report a data error